Brain Signal Modeling for Antidepressant Response Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antidepressant treatments for depression show only a small overall advantage over placebo, and there is a need for objective measures to stratify depressed patients into those who benefit from antidepressants and those who do not, as clinical diagnosis does not account for biological heterogeneity among patients.
Innovation Solution
A Sparse Electroencephalography Latent SpacE Regression (SELSER) computational model is used to analyze brain signals such as EEG, TMS-EEG, MEG, fMRI, and fNIRS data to predict treatment outcomes for antidepressant-responsive depression phenotypes, identifying patients likely to benefit from specific treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antidepressant medications are used to treat depression, then treatment coverage is provided for depressed patients, but the overall advantage over placebo is small and does not effectively differentiate between patients who will respond and those who will not
Solution Approach 1:
The patent segments the heterogeneous depressed patient population into distinct subtypes based on brain signal patterns (EEG, fMRI, MEG). By dividing patients into response and non-response groups using machine learning models, the treatment approach is segmented to match biological phenotypes, thereby improving treatment efficacy while accounting for biological heterogeneity.
Solution Approach 2:
The patent applies local quality by tailoring treatment predictions to specific patient subgroups identified through brain signal analysis. Instead of a uniform treatment approach, the system identifies local characteristics (neural patterns) of different patient phenotypes and predicts treatment response specifically for each subtype, allowing personalized treatment selection.
2Ease of operation
If clinical diagnosis is used to identify depressed patients, then treatment can be initiated, but the diagnosis does not account for biological heterogeneity and cannot predict treatment response
Solution Approach 1:
The patent introduces brain signal measurements (EEG, fMRI, MEG) as an intermediary between clinical diagnosis and treatment response prediction. These intermediate biomarkers capture biological heterogeneity that clinical diagnosis alone cannot detect, serving as a bridge to predict treatment response while maintaining the simplicity of initial clinical assessment.
Solution Approach 2:
The patent replaces the purely clinical/mechanical diagnosis system with a neurobiological measurement system. Instead of relying solely on symptom-based clinical assessment, the system substitutes brain signal measurements and machine learning analysis to objectively predict treatment response, thereby improving measurement precision.
3Productivity
If a uniform treatment approach is applied to all depressed patients, then treatment implementation is simplified, but treatment efficacy is reduced due to biological differences among patients
Solution Approach 1:
The patent performs preliminary action by predicting treatment response before treatment initiation using brain signal analysis and machine learning models. This advance prediction allows patients to be pre-stratified into likely responders and non-responders, enabling personalized treatment selection before treatment begins, thereby improving both implementation efficiency and outcome reliability.
Data Source
AI summary
Provided herein are, inter alia, methods for identifying subjects suffering from depression that will respond to treatment with an antidepressant.